| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/31/2007 | CA2630039A1 Azetidine derivatives as glyt1 inhibitors |
| 05/31/2007 | CA2629995A1 Chemical process for the preparation of an amido-phenoxybenzoic acid compound |
| 05/31/2007 | CA2629935A1 (r)-arylalkylamino derivatives and pharmaceutical compositions containing them |
| 05/31/2007 | CA2629899A1 Methods for wound healing |
| 05/31/2007 | CA2629800A1 Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity |
| 05/31/2007 | CA2629745A1 Morpholine type cinnamide compound |
| 05/31/2007 | CA2629738A1 Novel indolizine derivatives, method for preparing same and therapeutic compositions comprising same |
| 05/31/2007 | CA2629560A1 Pharmaceutical compositions comprising buprenorphine |
| 05/31/2007 | CA2629554A1 4-aminopyrimidine-5-thione-derivatives for the treatment of cancer |
| 05/31/2007 | CA2629544A1 Pyridylsulfonamide derivatives, their manufacture and use as antineoplastic agents |
| 05/31/2007 | CA2629527A1 2-(phenyl or heterocyclic)-1h-phenantrho[9,10-d]imidazoles as mpges-1 inhibitors |
| 05/31/2007 | CA2629512A1 Bicyclic cinnamide compound and prophylactic or therapeutic uses thereof |
| 05/31/2007 | CA2629457A1 Spirolactam bicyclic cgrp receptor antagonists |
| 05/31/2007 | CA2629454A1 Bicyclic spirohydantoin cgrp receptor antagonists |
| 05/31/2007 | CA2629421A1 Spirohydantoin tricyclic cgrp receptor antagonists |
| 05/31/2007 | CA2629415A1 Spirolactam tricyclic cgrp receptor antagonists |
| 05/31/2007 | CA2629409A1 Spirolactam aryl cgrp receptor antagonists |
| 05/31/2007 | CA2629406A1 Spirohydantoin aryl cgrp receptor antagonists |
| 05/31/2007 | CA2629196A1 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations |
| 05/31/2007 | CA2629192A1 Indole orexin receptor antagonists |
| 05/31/2007 | CA2629160A1 Methods for reducing the amount of proinflammatory substance in animal tissue or body fluid |
| 05/31/2007 | CA2629122A1 Novel thiophene derivatives |
| 05/31/2007 | CA2629082A1 Aerosol formulation for inhalation containing an anticholinergic agent |
| 05/31/2007 | CA2629074A1 Aerosol formulation for inhalation containing an anticholinergic agent |
| 05/31/2007 | CA2629073A1 Aerosol formulation for inhalation containing an anticholinergic agent |
| 05/31/2007 | CA2629070A1 Aerosol formulation for inhalation containing an anticholinergic agent |
| 05/31/2007 | CA2628958A1 Thiazoles for the treatment of proliferative disorders |
| 05/31/2007 | CA2628947A1 Aerosol formulation for inhalation containing an anticholinergic agent |
| 05/31/2007 | CA2628920A1 Pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors |
| 05/31/2007 | CA2628917A1 Pharmaceutical compositions |
| 05/31/2007 | CA2628542A1 Substituted aminophenylsulfonamide compounds as hiv protease inhibitor |
| 05/31/2007 | CA2628540A1 Aminophenylsulfonamide derivatives as hiv protease inhibitor |
| 05/31/2007 | CA2628538A1 Indanyl-and tetrahydronaphthyl-amino-azoline compounds for combating animal pests |
| 05/31/2007 | CA2628527A1 Modulators of the h3 receptor useful for the treatment of disorders related thereto |
| 05/31/2007 | CA2628476A1 Pharmaceutical for use in the treatment of ureterolithiasis |
| 05/31/2007 | CA2628475A1 Process for preparing pyridinamine polymorphs |
| 05/31/2007 | CA2628330A1 F,g,h,i and k crystal forms of imatinib mesylate |
| 05/31/2007 | CA2628313A1 Composition and method for efficient delivery of nucleic acids to cells using chitosan |
| 05/31/2007 | CA2628227A1 Chemical synthesis of a highly potent epothilone |
| 05/31/2007 | CA2628146A1 Salts of inducible nitric oxide synthase dimerization inhibitors |
| 05/31/2007 | CA2628137A1 A therapeutic composition containing an organosilane quaternary compound and hydrogen peroxide for treating skin disorders |
| 05/31/2007 | CA2626933A1 Pharmaceutical composition |
| 05/31/2007 | CA2625404A1 Bilayer tablet comprising telmisartan and diuretic |
| 05/31/2007 | CA2625299A1 Crystal forms of cinacalcet hci and processes for their preparation |
| 05/31/2007 | CA2624361A1 Methods of using small molecule compounds for neuroprotection |
| 05/31/2007 | CA2623018A1 Pharmaceutical compositions of telmisartan |
| 05/31/2007 | CA2602066A1 Aloe vera extract, method of producing aloe vera extract, and hyperglycemia improving agent |
| 05/31/2007 | CA2593718A1 Napthyridine compounds as rock inhibitors |
| 05/30/2007 | EP1790728A2 Imaging, diagnosis and treatment of disease |
| 05/30/2007 | EP1790725A2 Proteins named after FCTRX and nucleic acids encoding same |
| 05/30/2007 | EP1790653A2 Novel polymorphic form of 17-beta-(n-ter.butyl carbamoyl)-4-aza-5-alpha-androst-1-en-3-one and a process for preparing it |
| 05/30/2007 | EP1790652A1 Polycyclic guanine phosphodiesterase V inhibitors |
| 05/30/2007 | EP1790651A1 A1 adenosine receptor antagonists |
| 05/30/2007 | EP1790650A1 Novel substituted imidazole derivatives |
| 05/30/2007 | EP1790649A1 Substituted bicyclic pyrimidone derivatives |
| 05/30/2007 | EP1790648A1 Use of procyanidin B2 for the preparation of a medicament for the treatment of amyloid and synuclein diseases |
| 05/30/2007 | EP1790646A1 Isoquinoline und benzo[h]isoquinoline derivatives, their preparation and their therapeutical application as antagonists of histamine H3 receptor . |
| 05/30/2007 | EP1790644A1 Substituted benzopyrans as selective estrogen receptor-beta agonists |
| 05/30/2007 | EP1790643A1 Quinuclidine compounds having quaternary ammonium group, it's preparation method and use as blocking agents of acetycholine |
| 05/30/2007 | EP1790642A1 Biologically active methylene blue derivatives |
| 05/30/2007 | EP1790641A1 Triazole derivative or salt thereof |
| 05/30/2007 | EP1790640A1 Novel imidazolidine derivative and use thereof |
| 05/30/2007 | EP1790639A1 Compound containing basic group and use thereof |
| 05/30/2007 | EP1790638A1 Carbamoylpyridone derivative having hiv integrase inhibitory activity |
| 05/30/2007 | EP1790637A1 Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient |
| 05/30/2007 | EP1790636A1 Piperidine derivatives and use thereof |
| 05/30/2007 | EP1790357A2 Perorally administrable antimicrobial composition |
| 05/30/2007 | EP1790356A1 Preparation containing iron(III)-complexes and redox substances |
| 05/30/2007 | EP1790355A1 Propagation agent and propagation method for natural killer cell |
| 05/30/2007 | EP1790353A1 Combined use of a GLP-1 compound and a modulator of diabetic late complications |
| 05/30/2007 | EP1790348A2 Use of uridine for the treatment of inflammations and/or hemostasis |
| 05/30/2007 | EP1790347A1 High dose ibandronate formulation |
| 05/30/2007 | EP1790346A2 Use of bile acid or bile salt fatty acid conjugates |
| 05/30/2007 | EP1790345A1 Triazin beta-secretase inhibitors |
| 05/30/2007 | EP1790344A2 Methods for treatment of disease-induced peripheral neuropathy and related conditions |
| 05/30/2007 | EP1790343A1 Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
| 05/30/2007 | EP1790342A1 Pyridopyrazine derivatives and their use as signal transduction modulators |
| 05/30/2007 | EP1790341A1 Medicine having analgesic effects |
| 05/30/2007 | EP1790340A2 Combination chemotherapy |
| 05/30/2007 | EP1790339A1 Composition for prevention of occurrence of cardiovascular event |
| 05/30/2007 | EP1790338A1 Therapeutic agent for keratoconjunctiva disorder |
| 05/30/2007 | EP1790337A2 Methods and compounds for treating depression and other disorders |
| 05/30/2007 | EP1790336A1 Composition for capsule film, capsule film, and capsule made with the same |
| 05/30/2007 | EP1790334A2 Pharmacological inducement of the fed mode for enhanced drug administration to the stomach |
| 05/30/2007 | EP1790333A1 Gastroresistant tablet comprising a butyric acid compound |
| 05/30/2007 | EP1790331A1 Use of pyridoxal-5-phosphate for the treatment of cardiovascular and related pathologies |
| 05/30/2007 | EP1790329A1 Humectant containing alpha-glycosyl glycyrrhizin as active ingrediant and use thereof |
| 05/30/2007 | EP1790238A1 Whitening composition containing reduced coenzyme q |
| 05/30/2007 | EP1790235A1 Method for producing capsinoid-containing microcapsule |
| 05/30/2007 | EP1790223A1 Organ arrest, protection and preservation |
| 05/30/2007 | EP1789633A2 Benzamide compounds |
| 05/30/2007 | EP1789552A2 Methods of regulating differentiation and treating of multiple myeloma |
| 05/30/2007 | EP1789549A1 Method for treating synovial sarcoma using sirna for fzd10 |
| 05/30/2007 | EP1789433A2 Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
| 05/30/2007 | EP1789431A1 Partial and full agonists of a1 adenosine receptors |
| 05/30/2007 | EP1789429A2 Bifunctional antibiotics for targeting rrna and resistance causing enzymes and for inhibition of anthrax lethal factor |
| 05/30/2007 | EP1789428A1 Monosaccharide derivatives |
| 05/30/2007 | EP1789422A1 Anti-inflammatory compounds |
| 05/30/2007 | EP1789421A1 Spiro-benzo[c]chromene derivatives useful as modulators of the estrogen receptors |
| 05/30/2007 | EP1789420A2 6H-[1]BENZOPYRANO[4,3-b]QUINOLINES AND THEIR USE AS ESTROGENIC AGENTS |